2. Academic Validation
  3. Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease

Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease

  • Cell Chem Biol. 2017 Aug 17;24(8):1029-1039.e7. doi: 10.1016/j.chembiol.2017.07.011.
Juliane Totzke 1,  Deepak Gurbani 2,  Rene Raphemot 3,  Philip F Hughes 1,  Khaldon Bodoor 4,  David A Carlson 1,  David R Loiselle 1,  Asim K Bera 2,  Liesl S Eibschutz 1,  Marisha M Perkins 3,  Amber L Eubanks 3,  Phillip L Campbell 5,  David A Fox 5,  Kenneth D Westover 6,  Timothy A J Haystead 7,  Emily R Derbyshire 8
Affiliations

Affiliations

  • 1 Department of Pharmacology and Cancer Biology, Duke University, Durham, NC 27710, USA.
  • 2 Departments of Biochemistry and Radiation Oncology, University of Texas, Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA.
  • 3 Department of Chemistry, Duke University, Durham, NC 27710, USA.
  • 4 Department of Pharmacology and Cancer Biology, Duke University, Durham, NC 27710, USA; Department of Applied Biology, Jordan University of Science and Technology, PO Box 3030, Irbid 22110, Jordan.
  • 5 University of Michigan, Division of Rheumatology and Clinical Autoimmunity Center of Excellence, Ann Arbor, MI 48109, USA.
  • 6 Departments of Biochemistry and Radiation Oncology, University of Texas, Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA. Electronic address: [email protected].
  • 7 Department of Pharmacology and Cancer Biology, Duke University, Durham, NC 27710, USA. Electronic address: [email protected].
  • 8 Department of Chemistry, Duke University, Durham, NC 27710, USA. Electronic address: [email protected].
PMID: 28820959 DOI: 10.1016/j.chembiol.2017.07.011
Abstract

Tumor necrosis factor alpha (TNF-α) has both positive and negative roles in human disease. In certain cancers, TNF-α is infused locally to promote tumor regression, but dose-limiting inflammatory effects limit broader utility. In autoimmune disease, anti-TNF-α Antibodies control inflammation in most patients, but these benefits are offset during chronic treatment. TAK1 acts as a key mediator between survival and cell death in TNF-α-mediated signaling. Here, we describe Takinib, a potent and selective TAK1 inhibitor that induces Apoptosis following TNF-α stimulation in cell models of rheumatoid arthritis and metastatic breast Cancer. We demonstrate that Takinib is an inhibitor of autophosphorylated and non-phosphorylated TAK1 that binds within the ATP-binding pocket and inhibits by slowing down the rate-limiting step of TAK1 activation. Overall, Takinib is an attractive starting point for the development of inhibitors that sensitize cells to TNF-α-induced cell death, with general implications for Cancer and autoimmune disease treatment.

Keywords

autoimmune disease; cancer; drug discovery; enzyme kinetics; inflammatory disorders; kinase inhibitors.

Figures
Products